Cellceutix has completed enrolling a second cohort of patients with mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), two forms of inflammatory bowel disease (IBD), in its Phase 2 clinical trial evaluating brilacidin (PMX-30063). ... Read more